Recently, immune checkpoint inhibitors, such as antibodies against programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), have greatly improved cancer treatment. The gene discussed is PDCD1; the disease is cancer.